ECT and Memantine.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27602

Enrollment

Registered

2012-12-15

Start date

2012-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electroconvulsive therapy Cognitive side effects Memantine Electroconvulsieve therapie Cognitieve bijwerkingen Memantine Depression Depressie

Interventions

1. The experimental group will receive once daily 20 mg/d memantine during ECT. This will be titrated before commencing ECT

2. The control group will receive an identical placbo once daily.

Eligibility

Inclusion criteria

Inclusion criteria: DSM-IV criteria for unipolar or bipolar depression and a clinical indication for electroconvulsive treatment (ECT).

Exclusion criteria

Exclusion criteria: Patients with organic brain syndrome, Mini-Mental State Exam score lower than 24, schizophrenia, schizoaffective disorder, use of lithium or inadequate command of the Dutch language will be excluded.

Design outcomes

Primary

Measure	Time frame
Scores on a standard cognitive testbattery. This test is administered before, during and after ECT and at follow-up. This testbattery has been proven to be sensitive to cognitive side-effects of depression and also for the ECT effects in depression.	—

Contacts

Public ContactR.M. Kok

Parnassia Psychomedical Center Mangostraat 1

r.kok@parnassia.nl+31 (0)88 3575252

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)